Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) shares were down 6% on Wednesday . The company traded as low as $47.36 and last traded at $47.0710. Approximately 55,624 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 1,203,093 shares. The stock had previously closed at $50.08.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Wells Fargo & Company cut their price target on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 5th. Piper Sandler cut shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $85.00 to $55.00 in a research report on Tuesday, May 5th. Mizuho dropped their price objective on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Finally, Stifel Nicolaus reduced their target price on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $81.05.
View Our Latest Stock Analysis on INSP
Inspire Medical Systems Trading Down 4.8%
Inspire Medical Systems (NYSE:INSP – Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.28) by $0.38. The company had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, analysts expect that Inspire Medical Systems, Inc. will post 0.93 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Inspire Medical Systems
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP purchased a new stake in shares of Inspire Medical Systems during the fourth quarter valued at approximately $203,929,000. M&T Bank Corp purchased a new position in shares of Inspire Medical Systems in the fourth quarter worth $85,871,000. Deerfield Management Company L.P. increased its stake in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares during the period. Morgan Stanley raised its holdings in Inspire Medical Systems by 179.5% during the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after buying an additional 809,121 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. purchased a new stake in Inspire Medical Systems during the 4th quarter valued at $61,619,000. Institutional investors own 94.91% of the company’s stock.
About Inspire Medical Systems
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
See Also
- Five stocks we like better than Inspire Medical Systems
- Why Penguin Solutions May Be the Smartest AI Infrastructure Stock
- Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already There
- 3 Beaten-Down Trades That Could Pay Off in a Market Correction
- 5 Dividend Kings to Buy in July with Irristable Value and Yield
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
